Alvotech Reports Record-Breaking First Half of 2025 Amid Strong Biosimilar Sales

August 27, 2025

Alvotech achieves a remarkable financial turnaround in 2025, reporting a net profit driven by strong biosimilar sales and strategic partnerships.

Canadian RWE Shows Comparable Outcomes Between Etanercept Biosimilars, Originator

August 26, 2025

Biosimilar Romiplostim Shows Equivalence to Reference Product for Chronic ITP

August 25, 2025

The Top 5 Biosimilar Articles for the Week of August 18

August 22, 2025

Ten Years of Data Support Safety of Biosimilar Filgrastim for Donor Mobilization

August 22, 2025

Increasing Biosimilar Use Reflects Changing Practice in Pediatric IBD Care

June 25th 2025

By Skylar Jeremias

Article

Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory bowel disease (IBD) among children and young adults.

Omalizumab Biosimilar Matches Reference Product in Chronic Spontaneous Urticaria

June 24th 2025

By Skylar Jeremias

Article

CT-P39, an omalizumab biosimilar, shows comparable efficacy and safety to the original in treating chronic spontaneous urticaria, enhancing patient access.

BioRationality: Questioning Experts and Journals Reporting on Biosimilar Bill to Remove Interchangeability

June 23rd 2025

By Sarfaraz K. Niazi, PhD

Article

The debate over the Biosimilar Red Tape Elimination Act raises critical concerns about FDA standards, physician trust, and patient safety in biosimilars.

Long-Term Durability and Cost-Effectiveness of Adalimumab Biosimilars in Pediatric IBD

June 22nd 2025

By Deana Ferreri, PhD

Article

A real-world study reveals that pediatric patients with IBD achieve high remission rates and cost savings using adalimumab biosimilars over time.

The Top 5 Biosimilars Articles for the Week of June 16

June 20th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of June 16, 2025.

Tocilizumab Biosimilar CT-P47 Shows Promise for Rheumatoid Arthritis Self-Administration

June 19th 2025

By Cameron Santoro

Article

Tocilizumab biosimilar CT-P47, administered via autoinjector, offers comparable efficacy and a consistent safety profile to reference tocilizumab in patients with rheumatoid arthritis.

Strengthening Diabetes Care With Purpose-Built Data Infrastructure

June 18th 2025

By Skylar Jeremias

Article

Explore how real-world evidence and biosimilars enhance insulin access and adherence, improving diabetes care and outcomes for patients who have type 2 diabetes.

FDA Approves Steqeyma for Children With Plaque Psoriasis, Psoriatic Arthritis

June 17th 2025

By Skylar Jeremias

Article

Celltrion's FDA approval of Steqeyma enhances pediatric psoriasis treatment, offering flexible dosing options for children with chronic inflammatory conditions.

Eye on Pharma: Keytruda Biosimilar Deal; German Court Bans Imraldi; New Biosimilars for Japan

June 17th 2025

By Skylar Jeremias

Article

Alvotech and Dr. Reddy's partner to develop a Keytruda biosimilar, a German court bans Humira biosimilar over patent dispute, and Samsung Bioepis enters a strategic agreement with NIPRO Corporation in Japan.

New Data Support Hulio as an Interchangeable Adalimumab Option

June 16th 2025

By Skylar Jeremias

Article

The new data were collected to fulfill the FDA's requirements to designate adalimumab-fkjp (Hulio) as interchangeable with Humira, enhancing access to affordable biologics for chronic plaque psoriasis treatment.